Small molecule · Inhibitor of PRMT5 · developed by BRISTOL MYERS SQUIBB
Navlimetostat is an orally bioavailable, methylthioadenosine (MTA)-selective inhibitor of protein arginine methyltransferase 5 (PRMT5). It binds PRMT5 complexed with MTA, which is elevated in MTAP-deleted cancer cells, reducing histone arginine methylation, dysregulating RNA splicing and decreasing pRb, and is being studied in MTAP-deleted non-small cell lung cancer and solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07063745 | Phase 2/3 | Metastatic Non-small Cell Lung Cancer With MTAP Deletion | Recruiting | BMY |
| NCT07492680 | Phase 2 | Solid Tumors | Recruiting | BMY |
| NCT07777133 | Phase 1 | Healthy Female Participants | Recruiting | BMY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy Female ParticipantsMetastatic Non-small Cell Lung Cancer With MTAP DeletionSolid Tumors
Updated Nov 15, 2026. Something wrong or missing? Report it on the BMY page.
See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BMY catalysts and pipeline →